Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Eagle Pharmaceuticals (EGRX) PT Lowered to $64 at RBC Capital
November 2, 2018 7:01 AM EDTRBC Capital analyst Randall Stanicky lowered the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $64.00 (from $84.00) while maintaining an Outperform rating.
Stanicky said results place a spotlight on recent pipeline setbacks and outlook.
... MoreEagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss
November 1, 2018 6:51 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.91, $0.07 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.23 million.
While we were disappointed in the outcome of the fulvestrant trial, we believe in the strength of the remaining products in our pipeline and... More
